Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 5,443 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: cohort 3 Clear all

Conditions: Diffuse Large B-cell Lymphoma
Interventions: GCS-100, Etoposide; Dexamethasone; Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Gastric Cancer, Esophageal Cancer, Stomach Cancer, Esophagus Cancer, Gastroesophageal Junction Cancer
Interventions: CA-4948, Nivolumab, Pembrolizumab, Trastuzumab, mFOLFOX7; Drug · Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations, FGFR3, FGFR3 Overexpression, FGFR3 Receptor, FGFR3 Protein Overexpression, Ovarian Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Lung Cancer, Gastric Cancer
Interventions: [225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab; Drug · Biological
Lead sponsor: Fusion Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Duarte, California • San Francisco, California • Iowa City, Iowa + 1 more

Conditions: Diabetes Mellitus
Interventions: HM11260C, Placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Ohio City, Ohio

Conditions: Atopic Dermatitis
Interventions: EDP1815, Placebo; Drug
Lead sponsor: Evelo Biosciences, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 27
States / cities: Birmingham, Alabama • Fountain Valley, California • Fremont, California + 22 more

Conditions: Toxicity
Interventions: N-Methanocarbathymidine, Placebo Capsule; Drug · Other
Lead sponsor: N&N Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Acute Myeloid Leukemia
Interventions: Brequinar/Brequinar + Ribavirin; Drug
Lead sponsor: Clear Creek Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 6
States / cities: Duarte, California • Boston, Massachusetts • Cleveland, Ohio + 1 more

Conditions: HIV-1 Infection
Interventions: Zinc and SAMe; Dietary Supplement
Lead sponsor: Emory University; Other
Eligibility: 21 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Duchenne Muscular Dystrophy
Interventions: Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3, Sevasemten Dose 4, Sevasemten Dose 5, Placebo; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 4 Years to 9 Years · Male only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 14
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 11 more

Conditions: Obstructive Sleep Apnea
Interventions: Custom CPAP mask; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Myelofibrosis
Interventions: LY5830966; Drug
Lead sponsor: Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 13
States / cities: Palo Alto, California • Tampa, Florida • Kansas City, Kansas + 8 more

Conditions: Metastatic Breast Cancer With Intracranial Metastases
Interventions: cabazitaxel, lapatinib; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 4
States / cities: Fort Myers, Florida • St. Petersburg, Florida • Cincinnati, Ohio + 1 more

Conditions: Congenital Adrenal Hyperplasia
Interventions: Abiraterone acetate; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 2 Years to 9 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 4
States / cities: Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Radium-223 dichloride (Xofigo, BAY 88-8223), Pembrolizumab; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Marcos, California

Conditions: Ventricular Assist Device, Advanced Heart Failure, Anticipatory Guidance
Interventions: Not listed
Lead sponsor: Bryan Heart; Other
Eligibility: 19 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Lincoln, Nebraska • Milwaukee, Wisconsin

Conditions: Cytomegalovirus Infection
Interventions: Brincidofovir, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 26
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 21 more

Conditions: CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL), Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
Interventions: Lonitoclax (ZE50-0134); Drug
Lead sponsor: Lomond Therapeutics Holdings, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Louisville, Kentucky • Chapel Hill, North Carolina • Cincinnati, Ohio + 2 more

Conditions: Parenting, Family Relationships
Interventions: Relationship Education, Employment Services; Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,029 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Renal Cell Carcinoma
Interventions: SBRT, RFA; Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy Participants
Interventions: INCB161734, Itraconazole, Rifampin, Esomeprazole, Famotidine; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Clear Cell Renal Carcinoma
Interventions: MK-3475, Bevacizumab; Drug
Lead sponsor: Arkadiusz Z. Dudek, MD; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 9
States / cities: Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan + 5 more

Conditions: Neuroblastoma, Osteosarcoma
Interventions: iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Months and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2044
U.S. locations: 2
States / cities: Atlanta, Georgia • Chapel Hill, North Carolina

Conditions: Prostate Cancer Recurrent, Biochemical Recurrent Prostate Cancer
Interventions: MBM-02; Drug
Lead sponsor: Matrix Biomed, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Marina del Rey, California

Conditions: Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
Interventions: Emavusertib, Ibrutinib; Drug
Lead sponsor: Curis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 27
States / cities: Phoenix, Arizona • Duarte, California • Santa Monica, California + 19 more

Search by objective public record fields.

GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis

Evaluating the Safety and Plasma Levels of N-Methanocarbathymidine (N-MCT) in Normal Patients

A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Researching Alveolar Macrophage Improvements With Supplements in HIV

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

3D Printer Modified CPAP Mask for Obstructive Sleep Apnea

A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1

Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

Multi-Site Feasibility Testing of the Ventricular Assist Device Anticipatory Guidance Tool

Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

Montefiore Medical Center Healthy Marriage and Relationship Education Program

Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma

A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)